Who Is (and Isn't) a Good Candidate for GLP-1 Treatment?

GLP-1 medications get discussed online as though eligibility is just a BMI number. It isn't. Prescribing decisions involve a genuine clinical screening process, and understanding it matters — both so you know what to expect from a proper consultation, and so you can spot the difference between careful prescribing and a website that just wants your card details.

The baseline: BMI and comorbidity criteria

Across the major clinical trials and prescribing guidelines, eligibility generally follows a consistent pattern: a BMI of 30 kg/m² or higher on its own, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity such as hypertension, sleep apnea, prediabetes, or dyslipidemia (ClinicalTrials.gov, NCT07244445; NCT07213323). Some trial protocols use a slightly lower threshold of 24–28 kg/m² when a comorbidity is present, reflecting some variation in criteria between programmes and regions (ClinicalTrials.gov, NCT07611552).

This is the starting filter, not the full picture. As one clinical resource puts it plainly: qualifying on BMI means little if a contraindication applies — that screening step is what separates genuine medical care from a sales funnel (JumpstartMD, 2026).

Who is typically excluded, regardless of BMI

Personal or family history of medullary thyroid carcinoma (MTC) or MEN2. This is the most consistently cited exclusion across trial protocols and product labelling. In rodent studies, GLP-1 medications caused thyroid C-cell tumours; whether this risk translates to humans remains unknown, but both semaglutide and tirzepatide carry a boxed warning and exclude anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2, a genetic condition that predisposes to it (JumpstartMD, 2026; ClinicalTrials.gov, NCT07096063).

Pregnancy, planned pregnancy, or breastfeeding. GLP-1 medications aren't used during pregnancy — weight loss provides no benefit to the fetus and may cause harm. Product labelling for Wegovy specifically instructs stopping the medication once pregnancy is recognised, and discontinuing at least two months before a planned pregnancy, due to semaglutide's long half-life (JumpstartMD, 2026).

A history of pancreatitis. Several trial protocols exclude people with a history of chronic or acute pancreatitis as a standard safety criterion (ClinicalTrials.gov, NCT07284979).

Significant gastric motility conditions. Because GLP-1 medications work partly by slowing gastric emptying, trial protocols typically exclude people with known clinically significant gastric-emptying abnormalities, or those on medications that directly affect gastrointestinal motility (ClinicalTrials.gov, NCT07284979).

Certain existing diagnoses. Depending on the specific medication and indication, exclusions across trial protocols also commonly include liver cirrhosis, short bowel syndrome, inflammatory bowel disease, severely weakened immune systems, and clinically unstable cardiovascular, hepatic, renal, or other systemic disease (ClinicalTrials.gov, NCT07213323).

A history of eating disorders. Some protocols specifically exclude people with a current or previous eating disorder diagnosis, reflecting the clinical judgement that appetite-suppressing medication is not appropriate in that context (ClinicalTrials.gov, NCT07457437).

Severe psychiatric history. Trial exclusion criteria for at least one head-to-head obesity trial specifically excluded people with a history of suicide attempt or significant active or unstable major depressive disorder or other severe psychiatric conditions (ClinicalTrials.gov, NCT07284979) — a reminder that mental health history is a genuine part of a responsible screening conversation, not an afterthought.

What a proper consultation should actually cover

Given how consistently these exclusion criteria show up across independent trial protocols, a responsible prescriber conversation should realistically cover: your personal and family medical history (particularly thyroid and endocrine conditions), current or planned pregnancy, any history of pancreatitis or digestive conditions, current medications, and your mental health history. If a provider skips most of this and moves straight to a prescription, that's worth treating as a red flag rather than convenience.

Being eligible isn't the same as being ready

Even for people who clear every screening criterion, eligibility on paper doesn't automatically mean the medication will be well tolerated, or that the weight lost will be the kind you actually want to lose. None of the exclusion criteria above say anything about protein intake, training, or what happens after you stop — those are separate questions entirely, and ones the prescribing conversation typically won't cover in depth.

If you've been cleared to start, or you're already on treatment, our While You're On It programme is built to handle exactly that part — nutrition and training support that runs alongside your medication so more of what you lose is fat, not muscle.

Thinking ahead to when treatment eventually ends is worth doing from day one, which is why we built a separate Coming Off It programme specifically for the tapering and maintenance phase.

If appetite changes are making it hard to hit your nutrition targets, our Alongside Daily Support powder is formulated to help close that gap.

And if you want a second, structured perspective on your specific situation before or after your prescriber consultation, our 1:1 coaching is there for exactly that.

The bottom line

BMI is the entry criterion for GLP-1 treatment, not the full eligibility picture. Thyroid cancer history, pregnancy, pancreatitis history, certain digestive and psychiatric conditions, and several other factors can rule someone out regardless of weight — and a proper screening conversation should cover all of it. If you've been cleared to start, the medication itself is only one part of getting a good outcome from it.

This article is for general information and isn't a substitute for medical advice. Eligibility for GLP-1 treatment should always be assessed by a qualified prescriber based on your full medical history.

References

ClinicalTrials.gov. (n.d.). Comparative effectiveness of tirzepatide and semaglutide in individuals at cardiovascular risk (NCT07096063). https://clinicaltrials.gov/study/NCT07096063

ClinicalTrials.gov. (n.d.). Efficacy and safety of KAI-9531 administered once weekly compared with semaglutide and placebo in participants living with obesity who do not have diabetes (NCT07284979). https://clinicaltrials.gov/study/NCT07284979

ClinicalTrials.gov. (n.d.). Function and lean mass preservation with resistance exercise during a GLP-1RA treatment (NCT07457437). https://clinicaltrials.gov/study/NCT07457437

ClinicalTrials.gov. (n.d.). Pistachio intake and nutrition-related outcomes in individuals on GLP-1 therapy (NCT07244445). https://clinicaltrials.gov/study/NCT07244445

ClinicalTrials.gov. (n.d.). Probiotic intervention for digestive health in obese patients initiating GLP-RA treatment (NCT07213323). https://clinicaltrials.gov/study/NCT07213323

ClinicalTrials.gov. (n.d.). Effects of inulin on cardiometabolic risk factors in individuals using GLP-1 RA medications for weight loss (NCT07611552). https://clinicaltrials.gov/study/NCT07611552

JumpstartMD. (2026, July 18). Who qualifies for GLP-1 weight loss medication? https://jumpstartmd.com/hub/glp1-weight-loss/who-qualifies-eligibility